Share Name Share Symbol Market Type Share ISIN Share Description
Midatech Pharma LSE:MTPH London Ordinary Share GB00BRTL9B63 ORD 0.005P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.50p -7.89% 17.50p 17.00p 18.00p 19.00p 17.50p 19.00p 217,538 11:44:44
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.8 -17.3 -31.0 - 10.71

Midatech Pharma Share Discussion Threads

Showing 376 to 399 of 400 messages
Chat Pages: 16  15  14  13  12  11  10  9  8  7  6  5  Older
DateSubjectAuthorDiscuss
18/10/2018
13:40
Yes, poor fellow
investopia
18/10/2018
12:09
Hasn't Woodford got masses of these ?!
value viper
18/10/2018
11:54
This is a disaster stock franklyWhat is going on
value viper
01/10/2018
11:29
Midatech Pharma will be presenting to investors on the evening of Thursday 4th October in London at the Proactive One2One Forum from 6pm. For details click here: https://tinyurl.com/yb3j5c7z
aim_trader
28/9/2018
10:55
I agree re misleading. Seems to me that once the mist clears on MTD201 with the regulators and a path to market is known then there may be interest in the co... Disappointed with this share....
gwatson56
28/9/2018
02:15
What a complete mess. The non bioequivalence of MTD201 means that the route to approval increases by a couple of years. This means that Midatech US has to be sold in a fire sale which means that the $7m loan needs to be repaid out of the proceeds. The previous comments about Midatech US being close to break even were clearly misleading.
jamtomorrow2
27/9/2018
11:57
"Upon completion of the Sale, Midatech is required to repay its outstanding loan to MidCap Financial of $7.0 million plus early repayment fees and deferred interest. The remaining proceeds of the Sale (i.e. after Midcap repayment and other transaction costs) are expected to be approximately $4.5 million...." They will end up with an initial sum of just $4.5m.
bandflex
27/9/2018
08:58
good to see the results and sale of US business being greeted with a burst of activity here - lol
luffness
14/9/2018
19:46
6 figure upfront for a product which is supposedly better than SLAR selling $1.6b pa! If that was the best they could do then they should be fired.
jamtomorrow2
13/9/2018
07:59
They will be looking to out licence p3 trial ,I would imagine they will be in discussion now it’s just a case of getting the right deal 6 figure upfront payment and double digit royalties
best1467
11/9/2018
09:39
But it’s not bioequivalent so as it could potentially now become a blockbuster the FDA are going to require a large Phase 3 on real patients. If it was bioequivalent they could have got away with a small trial on healthy volunteers. Big difference in cost and time.
jamtomorrow2
11/9/2018
07:17
Even biosimilars have to do a small efficacy phase III study and they are essentially exactly the same drug (with a few minor structural differences). So no way Midatech could get away without some efficacy data.
nobbygnome
10/9/2018
22:36
What did they say “Midatech̵7;s drug is better than Sandostatin LAR, and that drug’s sales are $1.6b pa, yet Midatech’s market cap is mysteriously only £16m”? I guess all will be revealed in Q1 2019 after the outcome of Midatech’s discussions with the FDA are revealed. What Phase 3 trial will the FDA demand? Midatech are hoping for some quick cheap trial versus SLAR in healthy volunteers. The FDA aren’t likely to agree to Midatech taking over a $1.6b market without a large scale trial on sick patients - I mean let’s get real here. In the unlikely event of some sort of victory against the FDA I’m sure Novartis would file a Citizens Petition for non compatibility. This could all take years to sort out. In the meantime Midatech has no money. So in a nutshell that’s why a company that could be worth $1b right now is valued at £16m. On the other hand Midatech does look a sitting duck to be taken over by Novartis for $200m thus allowing the original investors to bail out at breakeven. Interesting eh!
jamtomorrow2
10/9/2018
17:44
Heard about this for the first time today as it was featured in the London Evening Standard
cerrito
07/9/2018
14:56
buying continues apace ; stock stuck
value viper
07/9/2018
10:10
my money is on a placing here - qu. is , at what price and raising how much as always big spike on recent news (brought lots of buying of course) many must be nursing losses more half decent nibbling today and still wont budge OR seller in background of course (imv unlikely) something bubbling BUT actually they said recently they would assess NON DILUTIVE financing options (may be I'm wrong)
value viper
06/9/2018
10:33
I wonder whether the recent financing was dependent upon MTD201 being bioequivalent to SLAR. As it isn’t that would necessitate a further dilutionary fund raising at a very low price. This may explain the fall back in the price if MTPH is doing the financing rounds right now.
jamtomorrow2
03/9/2018
07:48
Sbtx RNS boom time.Big rerate to come
costax1654x
02/9/2018
14:04
Also, potential partners should be queuing up here. A 1.5bn/yr market with a product that is proving significantly better than what’s in the market today. FDA Approvals are part and parcel of pharma’a and allies to wonder drugs alike, so wouldn’t see this is a red-herring. The key is drug & additionally the new Tech.
zen12
02/9/2018
13:45
Similar companies also have these complications uswell so is nothing new. Think with drug being significantly superior and new Tech could be massive money spinner, interesting days and weeks ahead.
zen12
01/9/2018
09:24
Jam tomorrow is technically correct; it will make the phase III more complicated. However, overall the drug formulation is more valuable because it is superior. So swings and roundabouts really...... IMHO the technology platform is now a great valuable asset. Nobby
nobbygnome
01/9/2018
09:23
Finished near session highs Https://www.nasdaq.com/symbol/mtp
riddlerone
01/9/2018
09:20
"Following close behind was fellow pharma firm Midatech, shares in which rose 33.6 per cent to 34.7p after new data released today for its MTD201 drug suggested it could be better than a rival product made by Swiss firm Novartis, one of the world’s biggest pharmaceutical companies. MTD201 is being developed as a treatment for a hormonal disorder called acromegaly as well as for carcinoid cancer. Novartis has already cornered a large slice of the market with its Sandostatin LAR drug, but the interim data has shown MTD201 to be, at worst, a good alternative or, at best, a 'differentiated improved product" Http://www.dailymail.co.uk/money/investing/article-6118485/Sinclair-Pharma-topped-AIM-leaders-board-Chinese-takeover-offer-finally-arrived.html
riddlerone
01/9/2018
08:51
Not sure how you can view it as a negative with a superior product a partner should be found with milestone and royalties down the line which even in the short term should give a substantial lift to the current valuation.
best1467
Chat Pages: 16  15  14  13  12  11  10  9  8  7  6  5  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20181019 00:20:26